Current situation and issues for stability prediction of biopharmaceuticals

DOI
  • SHIBATA Hiroko
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences
  • KIYOSHI Masato
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences
  • NAKAKIDO Makoto
    Department of Bioengineering, School of Engineering, The University of Tokyo
  • ITO Yuji
    Chemistry Program, Department of Science, Graduate School of Science and Engineering, Kagoshima University
  • NISHIKAWA Atsushi
    Pharmaceuticals and Medical Devices Agency
  • HASHII Noritaka
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences
  • TADA Minoru
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences
  • TSUMOTO Kouhei
    Department of Bioengineering, School of Engineering, The University of Tokyo
  • ISHII-WATABE Akiko
    Division of Biological Chemistry and Biologicals, National Institute of Health Sciences

Bibliographic Information

Other Title
  • バイオ医薬品の安定性予測に関する現状と課題

Search this article

Description

<p>Proteins, which are the active ingredients of biopharmaceuticals, have large molecular weights and complex structures compared to chemical substances. Various physical and chemical changes of proteins occur in the process of manufacturing, storage, transportations and medical practice, which may lead to decrease of biological activity and aggregate formation, ultimately affecting the efficacy and safety of the products. Stability data are essential information for determining key elements of control strategies, such as molecular design, formulation design, primary packaging, and manufacturing processes, and are the basis for establishing product shelf-life. Developing next-generation antibodies with high medical importance and revolutionary properties tends to be required to shorten the development period. Thus, it is necessary to accumulate data on stability as early as possible in the development stage, and to understand possible physical and chemical changes quantitatively and qualitatively. However, the accumulation of stability data requires mush resources and time. Particularly it takes years to acquire stability data for setting the shelf-life, which is one of obstacles to rapid development. Therefore, it is highly expected that new technologies will be developed and utilized, such as methods for predicting stability of proteins using statistical analysis and predicting models from existing data and/or data obtained in a short period of time during accelerated tests. In this paper, we review the background, current situation, and general issues regarding stability evaluation of biopharmaceuticals, and discuss future issues.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top